Craig Hallum Forecasts Strong Price Appreciation for Eton Pharmaceuticals (NASDAQ:ETON) Stock

Eton Pharmaceuticals (NASDAQ:ETON) had its target price lifted by equities researchers at Craig Hallum from $30.00 to $35.00 in a research note issued to investors on Friday,Benzinga reports. The firm currently has a “buy” rating on the stock. Craig Hallum’s price objective would indicate a potential upside of 55.64% from the company’s current price.

Several other research firms have also recently issued reports on ETON. Weiss Ratings reiterated a “sell (d-)” rating on shares of Eton Pharmaceuticals in a research note on Thursday, January 22nd. HC Wainwright increased their target price on shares of Eton Pharmaceuticals from $35.00 to $37.00 and gave the stock a “buy” rating in a research note on Monday, March 2nd. Zacks Research raised Eton Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Thursday, January 1st. Finally, Wall Street Zen downgraded Eton Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, December 13th. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $32.67.

Eton Pharmaceuticals Trading Up 8.3%

Eton Pharmaceuticals stock traded up $1.72 during midday trading on Friday, reaching $22.49. The stock had a trading volume of 496,537 shares, compared to its average volume of 281,579. Eton Pharmaceuticals has a 52-week low of $11.09 and a 52-week high of $23.00. The company has a fifty day moving average of $16.59 and a 200 day moving average of $17.34. The firm has a market cap of $603.13 million, a price-to-earnings ratio of -89.92 and a beta of 1.19. The company has a quick ratio of 1.25, a current ratio of 1.63 and a debt-to-equity ratio of 1.19.

Eton Pharmaceuticals (NASDAQ:ETON) last posted its quarterly earnings data on Thursday, March 19th. The company reported $0.05 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.07). The business had revenue of $21.28 million for the quarter, compared to analysts’ expectations of $20.58 million. Eton Pharmaceuticals had a negative net margin of 9.50% and a negative return on equity of 11.32%. On average, analysts anticipate that Eton Pharmaceuticals will post -0.14 earnings per share for the current fiscal year.

Institutional Trading of Eton Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ETON. Millennium Management LLC raised its holdings in shares of Eton Pharmaceuticals by 156.3% in the first quarter. Millennium Management LLC now owns 355,929 shares of the company’s stock valued at $4,620,000 after buying an additional 217,042 shares during the last quarter. Goldman Sachs Group Inc. raised its holdings in Eton Pharmaceuticals by 34.9% during the first quarter. Goldman Sachs Group Inc. now owns 175,220 shares of the company’s stock worth $2,274,000 after purchasing an additional 45,341 shares in the last quarter. Jane Street Group LLC lifted its position in Eton Pharmaceuticals by 49.1% in the first quarter. Jane Street Group LLC now owns 95,919 shares of the company’s stock valued at $1,245,000 after purchasing an additional 31,596 shares during the period. Envestnet Asset Management Inc. boosted its holdings in Eton Pharmaceuticals by 33.1% in the 2nd quarter. Envestnet Asset Management Inc. now owns 23,050 shares of the company’s stock valued at $328,000 after purchasing an additional 5,734 shares in the last quarter. Finally, Geode Capital Management LLC increased its position in Eton Pharmaceuticals by 98.8% during the 2nd quarter. Geode Capital Management LLC now owns 592,865 shares of the company’s stock worth $8,450,000 after purchasing an additional 294,617 shares during the period. Hedge funds and other institutional investors own 27.86% of the company’s stock.

More Eton Pharmaceuticals News

Here are the key news stories impacting Eton Pharmaceuticals this week:

• Positive Sentiment: Analysts’ price targets show substantial upside — the mean target implies roughly a 49% upside versus the current share price, and Zacks notes analyst upgrades in estimates that can support further gains. Read More.
• Positive Sentiment: Revenue strength / record top‑line growth: Eton reported record Q4 revenue and beat consensus revenue estimates modestly, which supports the narrative of accelerating commercial traction in its rare‑disease portfolio. Read More.
• Neutral Sentiment: Earnings call materials and summaries are available for investors to assess management’s commentary on growth drivers and commercialization plans. Review the call summary for color on guidance and product rollouts. Read More.
• Neutral Sentiment: The full earnings call transcript is posted for detailed read‑through of management’s remarks and Q&A, useful for judging sustainability of revenue trends. Read More.
• Negative Sentiment: EPS miss and ongoing unprofitability: Eton reported $0.05 EPS versus a $0.12 consensus (miss of $0.07) and still posts a negative net margin and negative ROE, highlighting that profitability and cost control remain concerns despite revenue growth. Read More.
• Negative Sentiment: Analysts and media flagged the EPS shortfall in standalone coverage, which can weigh on near‑term sentiment even as estimates get revised upward. Read More.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.